Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Co., Ltd.
逸達生物科技股份有限公司
+886-2-2655-2658
+886-2-2655-2657

1. Rapid development and commercialization of new drugs using its proprietary drug delivery technology. Targeting indications through the 505(b)(2) regulatory pathway. Products under development are FP-001 (prostate cancer), FP-004 (opiate drug addiction), FP-002 (acromegaly), and FP-008 (diabetic retinopathy).

2. Rationally-designed small molecule candidates, designed through medicinal chemistry screening and lead optimization. Products currently under development are FP-025 (asthma / chronic obstructive pulmonary disease) and FP-020 (Alport syndrome).

New drugs in clinical trials are FP-001 LMIS 50mg (prostate cancer), currently in a multinational multi-center phase III registration study in the US, Europe and Taiwan, and FP-025 (a small molecule MMP-12 inhibitor for the treatment of asthma / chronic obstructive pulmonary disease), in a First-in-Human Phase I study in Taiwan.

Foresee Pharmaceuticals also has a US office.

3F, No. 19-3, Sanchong Rd, Nangang Dist, Taipei 115, Taiwan
115台北市南港區三重路19-3號3F
6576
TPEx

Send Message to listing owner

Foresee Pharmaceuticals Co., Ltd.